Hemp Supplements Face a Double Squeeze in 2026: New THC Caps and a Stalled CBD Pathway
By HiMiyer.com — March 23, 2026
Rescheduling Did Not Fix CBD
The federal rescheduling of cannabis — a major policy shift — did not automatically clear the regulatory path for hemp-derived CBD as a dietary supplement ingredient. The FDA's position rests on a separate legal foundation: Section 301(ll) of the Food, Drug, and Cosmetic Act, which excludes from the dietary supplement definition any substance that has been approved as a drug or authorized for investigation as a new drug. Because CBD (cannabidiol) was approved as a pharmaceutical drug under the brand name Epidiolex, the FDA has maintained that CBD cannot simultaneously be a legal dietary ingredient — a position it has not reversed.
New THC Limits
Separately, Congress enacted new statutory THC limits taking effect in late 2026 that tighten the definition of lawful hemp. The legislation excludes from the definition any THC or other cannabis derivatives with intoxicating or psychoactive properties above 0.3% by dry weight and caps total tetrahydrocannabinols in any single product container at 0.4 milligrams. The rules are designed to address intoxicating hemp derivatives and synthetic cannabinoids that have proliferated since the 2018 Farm Bill, but they introduce new testing and labeling obligations for mainstream hemp supplement brands.
Compliance Burdens
Manufacturers now face a two-front compliance challenge: demonstrating that their hemp products stay within the new THC thresholds while simultaneously operating without confirmed legal status for CBD as a dietary ingredient. Many companies have absorbed the FDA's CBD position as a de facto enforcement-discretion environment — the agency has not actively pursued most hemp supplement brands — but that posture could shift as regulatory priorities evolve under the current administration.
Consumer Impact
For consumers, the most immediate effect is potential product reformulation. Brands selling broad-spectrum or full-spectrum hemp supplements with any detectable THC will need to ensure their products meet the new 0.4-milligram container cap. Isolate-based CBD products are less affected by the THC caps but remain in a legal gray zone under FDA's drug preclusion stance.
